BioLine RX Ltd Total Liabilities
BioLine RX Ltd total liabilities. Based on the latest financial reports, BioLine RX Ltd (BLRX) has total liabilities worth ILA16.75 Million ILA (≈ $44.90K USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See BLRX cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Total Liabilities of BioLine RX Ltd (2005–2025)
Total liabilities of BioLine RX Ltd from 2005 to 2025. This chart illustrates how BioLine RX Ltd's total liabilities have evolved over time, based on quarterly financial data. Check BioLine RX Ltd (BLRX) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
BioLine RX Ltd Competitors by Total Liabilities
The table below lists competitors of BioLine RX Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Alkali Metals Limited
NSE:ALKALI
|
India | Rs508.60 Million |
|
Comperia.pl S.A.
WAR:CPL
|
Poland | zł12.86 Million |
|
Holista Colltech Ltd
AU:HCT
|
Australia | AU$6.29 Million |
|
PowerBank Corporation
NEO:PBK
|
Canada | CA$105.51 Million |
|
AlphaTON Capital Corp.
NASDAQ:ATON
|
USA | $21.70 Million |
|
JE Cleantech Holdings Ltd
NASDAQ:JCSE
|
USA | $13.31 Million |
|
Vantage Corp
NYSE MKT:VNTG
|
USA | $8.17 Million |
|
Aakash Exploration Services Limited
NSE:AAKASH
|
India | Rs422.38 Million |
Liability Composition Analysis (2005–2025)
This chart breaks down BioLine RX Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see BioLine RX Ltd total assets.
Liquidity & Leverage Metrics
BioLine RX Ltd Total Liabilities Ratios Explained
BioLine RX Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.20 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.22 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.50 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how BioLine RX Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for BioLine RX Ltd (2005–2025)
The table below shows the annual total liabilities of BioLine RX Ltd from 2005 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ILA17.56 Million ≈ $47.09K |
-30.97% |
| 2024-12-31 | ILA25.45 Million ≈ $68.22K |
-49.81% |
| 2023-12-31 | ILA50.70 Million ≈ $135.93K |
+98.50% |
| 2022-12-31 | ILA25.54 Million ≈ $68.48K |
+91.99% |
| 2021-12-31 | ILA13.30 Million ≈ $35.67K |
-47.33% |
| 2020-12-31 | ILA25.26 Million ≈ $67.72K |
+25.13% |
| 2019-12-31 | ILA20.19 Million ≈ $54.12K |
+35.37% |
| 2018-12-31 | ILA14.91 Million ≈ $39.98K |
+84.46% |
| 2017-12-31 | ILA8.08 Million ≈ $21.67K |
+106.65% |
| 2016-12-31 | ILA3.91 Million ≈ $10.49K |
+5.96% |
| 2015-12-31 | ILA3.69 Million ≈ $9.90K |
-16.09% |
| 2014-12-31 | ILA4.40 Million ≈ $11.80K |
-46.76% |
| 2013-12-31 | ILA8.27 Million ≈ $22.16K |
-11.47% |
| 2012-12-31 | ILA9.34 Million ≈ $25.03K |
+37.18% |
| 2011-12-31 | ILA6.81 Million ≈ $18.25K |
-69.96% |
| 2010-12-31 | ILA22.65 Million ≈ $60.73K |
-45.06% |
| 2009-12-31 | ILA41.23 Million ≈ $110.54K |
+10.41% |
| 2008-12-31 | ILA37.34 Million ≈ $100.11K |
+51.61% |
| 2007-12-31 | ILA24.63 Million ≈ $66.03K |
+15.27% |
| 2006-12-31 | ILA21.37 Million ≈ $57.29K |
+173.07% |
| 2005-12-31 | ILA7.83 Million ≈ $20.98K |
-- |
About BioLine RX Ltd
BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the tr… Read more